Sagun Parakh - Department of Medicine, James Cook Hospital

基本信息

浏览量：28

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 109 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

P1.09C.03 IMMUNOResist: Defining the Immunophenotype of Immunotherapy Resistance with PD-L1 and CD8 Novel Tracer PET

F. Hegi-Johnson, T. Akhurst, T. John, A. Scott,S. Parakh, B. Blyth, S. Wong,M. MacManus

Journal of Thoracic Oncologyno. 10 (2024)

引用0浏览0引用

663P First-in-human, Phase I/II, Monotherapy, Dose-Escalation Study of Mrna-4359, an Mrna-Encoded PD-L1/IDO1 Antigen-Specific Therapy, in Advanced/refractory Solid Tumors

M.A. Khattak, R.J. Sullivan, M. Gutierrez, A. Jimeno,S.S. Thomas, G.V. Long,S. Kummar, A. Daud, A. Rohatgi,R.F. Sweis,J.E. Bauman, V. Boni,S. Parakh, H.N. Daghestani, J. Xu, Y. Li, M. Morrissey, M. Abadier, F. Barlaskar,D. Sarker

Annals of Oncology (2024)

引用0浏览0引用

ALKTERNATE: A Pilot Study Alternating Lorlatinib with Crizotinib in ALK+ Non-Small Cell Lung Cancer with Prior ALK-inhibitor Resistance

M. Itchins, S. Liang,C. Brown,T. Barnes,G. Marx,V. Chin,S. Kao,P.Y. Yip, A.J. Mersiades,A. Nagrial,V. Bray,G. Peters,S. Parakh, K. Garg,B.T. Li,M. McKay,K. O'Byrne,T. John,A.J. Gill,M. Molloy

JTO Clinical and Research Reportspp.100703-100703, (2024)

引用0浏览0引用

Pleural-based Primary Thoracic EBV-associated Lymphoepithelial Carcinoma

James A. Rickard, Elena Tarasenko,Jared Mathai,Khashayar Asadi,Sagun Parakh

Pathology (2024)

引用0浏览0WOS引用

Implementation of a Nurse-Led, Multidisciplinary Model of Care for Older Adults with Cancer: a Process Evaluation Protocol

Polly Hypatia Dufton, Elena Tarasenko, Katrina Midgley,Kathryn Lee,Ray Kelly,Jeremy Rodrigues,Paul Yates,Surein Arulananda,Sagun Parakh

BMJ OPENno. 1 (2024)

引用0浏览0WOS引用

202P Clinical Outcomes to Second-Line Treatment, after Failing Chemoimmunotherapy, in ES-SCLC

V.J. Andreas, M. Faltys, M. Alexander, J. Rogers,S. Parakh,S.E. Bowyer,L. Warburton, A. Fantoni,T.D. Clay,S. Arulananda, I. Sullivan,S.C-H. Kao,I. Pires Da Silva,L.J. Brown,B.G.M. Hughes,M. Itchins,B. Solomon,T. John

ESMO Open (2024)

引用0浏览0引用

ALKTERNATE: A Pilot Study Alternating Lorlatinib with Crizotinib in ALK-Positive NSCLC with Prior ALK Inhibitor Resistance

JTO CLINICAL AND RESEARCH REPORTSno. 9 (2024)

引用0浏览0WOS引用

A Phase II Trial of Alternating Osimertinib and Gefitinib Therapy in Advanced EGFR-T790M Positive Non-Small Cell Lung Cancer: OSCILLATE

NATURE COMMUNICATIONSno. 1 (2024)

引用0浏览0WOSNATURE引用

Preliminary Results from a First-in-human Trial of AMT-116, a Topoisomerase I Inhibitor Containing Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumors

Jim Coward, Ganessan Kichenadasse,John J. Park,Sagun Parakh,Gary Edward Richardson,Mark Voskoboynik,John D. Powderly,Zhengbo Song, Shutong Liu, Yaling Huang,Shu-Hui Liu,Xun Meng

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Lurbinectedin in Small Cell Lung Cancer: Real-World Experience of a Multicentre National Early Access Programme

Marliese Alexander,Jennifer Rogers,Sagun Parakh, Paul Mitchell,Timothy D. Clay,Steven Kao,Brett G. M. Hughes,Malinda Itchins,Benjamin Y. Kong,Nick Pavlakis,Benjamin J. Solomon,Thomas John

INTERNAL MEDICINE JOURNALno. 7 (2024): 1087-1096

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn